Indofarma Awaits Danantara Funding for Business Recovery

Ongoing Funding Discussions

PT Indofarma Tbk (INAF) is currently in discussions with Danantara regarding a potential funding injection that is crucial for the company's recovery and business strengthening efforts. According to Indofarma's President Director, Sahat Sihombing, the company has completed various supporting studies including work plans, product portfolios, and market certainty that have been submitted to Danantara.

Coordination with Holding Company

The management has been coordinating closely with Bio Farma (Persero), the holding company for state-owned pharmaceutical firms. This collaboration is essential as Bio Farma oversees the overall strategy for state-owned enterprises in the pharmaceutical sector. Sahat Sihombing mentioned that from Indofarma's side, they have fulfilled the necessary requirements for the funding application and are now waiting for Danantara's processing of their submission.

Planned Use of Funds

Indofarma intends to utilize the funding for supporting their restructuring program as outlined in their homologation agreement. The financial injection is expected to bolster the company's performance and help achieve their business objectives. The successful disbursement of these funds is considered critical for Indofarma's path to recovery and future growth in the competitive pharmaceutical industry.

Market Implications

The outcome of this funding request will have significant implications for Indofarma's financial health and operational capabilities. A successful funding injection could lead to improved market positioning and enhanced capacity to execute their business plans effectively.